Vaccine Contract Manufacturing Market Size

Vaccine Contract Manufacturing Market Size

Vaccine Contract Manufacturing Market size in 2023 was valued at USD 2.7 billion and is anticipated to showcase growth at 11% from 2024 and 2032. The trend of increased outsourcing in the vaccine contract manufacturing market is primarily driven by the need for cost efficiency and specialized expertise.

To get key market trends

  Download Free Sample

Pharmaceutical and biotechnology companies are increasingly relying on contract manufacturing organizations (CMOs) to handle vaccine production due to the high costs and complexities associated with building and maintaining in-house manufacturing facilities. Further, technological advancements, such as single-use bioreactors and automation, are enhancing production efficiency and flexibility, while the rising demand for complex biologics, including mRNA vaccine and viral vector vaccines, is pushing the industry towards more innovative vaccine platforms. CMOs are expanding their production capacities and geographically diversifying their operations to better meet global demand and mitigate supply chain risks.

Vaccine contract manufacturing is a service provided by specialized companies, often referred to as contract manufacturing organizations (CMOs), to produce vaccines on behalf of another company, such as a pharmaceutical firm, biotech company, or government agency. This arrangement allows the contracting company to leverage the expertise, facilities, and regulatory compliance capabilities of the CMO without having to invest in its own manufacturing infrastructure.